Genentech Could Initiate Lucentis Rolling BLA Filing As Early As December

Genentech could begin a rolling BLA filing for its neovascular (wet) age-related macular degeneration therapy Lucentis (ranibizumab) as early as December if the company is granted fast-track designation by FDA